HIF2Α INHIBITOR

Clinical trials for HIF2Α INHIBITOR explained in plain language.

Never miss a new study

Get alerted when new HIF2Α INHIBITOR trials appear

Sign up with your email to follow new studies for HIF2Α INHIBITOR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Terminated 1

New pill tested for Tough-to-Treat kidney cancer

Disease control Terminated

This study tested a new oral pill called NKT2152 for adults with advanced kidney cancer that had stopped responding to standard treatments. The first part aimed to find a safe and effective dose. The second part planned to see how well the pill could shrink tumors and control the…

Matched conditions: HIF2Α INHIBITOR

Phase: PHASE1, PHASE2 • Sponsor: NiKang Therapeutics, Inc. • Aim: Disease control

Last updated Mar 30, 2026 14:33 UTC

HIF2Α INHIBITOR

Get alerted when new HIF2Α INHIBITOR trials appear

New pill tested for Tough-to-Treat kidney cancer